Suppr超能文献

一种含有抗盐皮质激素孕激素屈螺酮的新型口服避孕药对肾素-醛固酮系统、体重、血压、糖耐量和脂质代谢的影响。

Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.

作者信息

Oelkers W, Foidart J M, Dombrovicz N, Welter A, Heithecker R

机构信息

Division of Endocrinology, Klinikum Benjamin Franklin (Steglitz), Freie Universität, Berlin, Germany.

出版信息

J Clin Endocrinol Metab. 1995 Jun;80(6):1816-21. doi: 10.1210/jcem.80.6.7775629.

Abstract

Combined hormonal oral contraceptives (OCs) may lead to a mild rise in blood pressure and body weight. In rare instances, large increments in blood pressure are measured. We investigated the effect of a combination of ethinyl estradiol (EE) plus a progestogen with antimineralocorticoid, i.e. natriuretic, properties [Drospirenone (DRSP)] on body weight, blood pressure, the renin-aldosterone system, atrial natriuretic factor, plasma lipids, and glucose tolerance. It is anticipated that this will lead to the development of an OC that does not raise body weight or blood pressure. Four groups of 20 women each received 30 micrograms EE plus 3 mg DRSP (group A), 20 micrograms EE plus 3 mg DRSP (group B), 15 micrograms EE plus 3 mg DRSP (group C), and, as a control OC, 30 micrograms EE plus 150 micrograms levonorgestrel (Microgynon, Schering; group D) for 6 months. During the OC-free control cycles before and after treatment and throughout treatment, the target parameters were measured. Between the pretreatment cycle and the sixth treatment cycle, mean body weight fell by 0.8 to 1.7 kg in groups A, B, and C (P < 0.05 vs. D), whereas it rose by 0.7 kg in group D. Systolic and diastolic blood pressures fell by 1-4 mm Hg in groups A, B, and C (significant for A and C vs. D) and increased by 1-2 mm Hg in group D. Renin substrate rose equally in all groups (P < 0.05), whereas PRA and plasma aldosterone rose significantly only in the DRSP groups, presumably due to sodium loss. In the DRSP groups, high density lipoprotein cholesterol rose (P < 0.05), in contrast to group D. Low density lipoprotein cholesterol fell slightly (P > 0.05), whereas triglyceride levels showed a stronger increase in the DRSP groups (P < 0.05) than in group D. All groups attained good cycle control; group A had the best. Side-effects were minimal. To our knowledge, this is the first report on a combined OC that leads to a small decrease in body weight and blood pressure. It may be especially beneficial for women susceptible for a gain in weight and a rise in blood pressure.

摘要

复方口服激素避孕药(OCs)可能导致血压和体重轻度升高。在极少数情况下,会测得血压大幅升高。我们研究了炔雌醇(EE)与具有抗盐皮质激素即利钠特性的孕激素(即屈螺酮(DRSP))联合使用对体重、血压、肾素 - 醛固酮系统、心房利钠因子、血脂和糖耐量的影响。预计这将促成一种不会增加体重或血压的OCs的研发。四组,每组20名女性,分别接受30微克EE加3毫克DRSP(A组)、20微克EE加3毫克DRSP(B组)、15微克EE加3毫克DRSP(C组),以及作为对照OC的30微克EE加150微克左炔诺孕酮(妈富隆,先灵公司;D组),为期6个月。在治疗前后的无OCs对照周期以及整个治疗期间,对目标参数进行测量。在预处理周期和第六个治疗周期之间,A组、B组和C组的平均体重下降了0.8至1.7千克(与D组相比,P < 0.05),而D组体重增加了0.7千克。A组、B组和C组的收缩压和舒张压下降了1 - 4毫米汞柱(A组和C组与D组相比有显著差异),D组升高了1 - 2毫米汞柱。所有组的肾素底物均同等升高(P < 0.05),而仅在DRSP组中,血浆肾素活性(PRA)和血浆醛固酮显著升高,可能是由于钠流失所致。与D组相比,DRSP组的高密度脂蛋白胆固醇升高(P < 0.05)。低密度脂蛋白胆固醇略有下降(P > 0.05),而DRSP组甘油三酯水平升高幅度比D组更大(P < 0.05)。所有组的月经周期控制良好;A组最佳。副作用最小。据我们所知,这是关于一种导致体重和血压小幅下降的复方OCs的首份报告。它可能对易体重增加和血压升高的女性特别有益。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验